Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce ... partnership with PTI Inspection Systems. Whitehouse Labs and PTI ... custom-tailored method development and validation programs using the ... agreement includes a more formal program that facilitates cross ... This enables a more effective team approach, especially as ...
(Date:5/28/2015)... Clinerion, an eClinical technology ... the Alliance for Clinical Research Excellence and ... operating in the public interest and dedicated ... quality, safety, integrity and operational effectiveness in ... pleased to announce their partnership for accelerating ...
(Date:5/27/2015)... The Academy of Model Aeronautics Foundation would like to ... Day. The third annual celebration will be August 15, 2015. ... aviation hobby nation-wide and to introduce model flying to the ... clubs to celebrate the hobby and share it with the ... also be a local event at the AMA headquarters in ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3
... to Move ... Science Forward, MUNICH, Germany, March 31 ... serving science, today,launched a number of innovative new products at Analytica 2008, ... - 4. The company,s new technologies are focused on enabling,customers to take ...
... Inc., a,biopharmaceutical company developing and commercializing therapies for,vascular disorders, ... full year 2007 financial results., 2007 Year ... clinical study -- Received FDA approval to ... Kinlytic(TM) -- Signed strategic licensing ...
... Calif., March 31 Varian, Inc.,(NasdaqGS: VARI) ... UltiMetal(TM),column for high temperature gas chromatography (GC), ... conditions. These highly durable columns,allow chemists to ... up,to 450 degrees Celsius. Based on a ...
Cached Biology Technology:Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 2Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 3Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 4Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 5Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 6Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 2ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 3ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 4ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 5ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 6ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 8ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 9ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 10New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS 2
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a novel gene therapy aimed at selectively turning off ... Parkinson's disease. , The gene therapy, described in the ... designed by Martha Bohn and her laboratory group at ... is Medical Research Council Professor and director of the ...
... mate is a big decision. And, at least for mice, it's ... In a series of experiments designed help scientists understand the brain ... mice to odors of either a male mouse alone or a ... of males linked to other females. , "Our data suggest that ...
... biological weapons are created equal. They are separated into ... the scariest: They are easy to spread, kill effectively ... system. One of these worrisome organisms is anthrax, which ... But work in Vince Fischetti's laboratory at Rockefeller University ...
Cached Biology News:Gene therapy 'turns off' mutation linked to Parkinson's disease 2When mice choose mates, experience counts 2Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... uses continuous chemical suppression and thermally stabilized ... accurate determinations of common anions and cations ... quick to equilibrate, and fully automated with ... you achieve maximum sample throughput at minimum ...
Biology Products: